Attached files

file filename
EX-16.1 - EXHIBIT 16.1 - Rasna Therapeutics Inc.v453982_ex16-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): November 22, 2016

 

RASNA THERAPEUTICS, INC.

 

(Exact Name of Registrant as Specified in Charter)

 

Nevada   333- 191083   39-2080103

(State or other jurisdiction

of incorporation)

  (Commission File Number)   (IRS Employer Identification No.)
         

420 Lexington Avenue, Suite 2525, New York, NY

  10170
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 201-994-9936

 

 

 

(Former name or former address, if changed since last report)

 

Copies to:

Jeffrey Fessler, Esq.

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, New York 10112

Telephone: (212) 653-8700

Facsimile: (212) 653-8701

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 4.01Change in Registrant’s Certifying Accountant

 

On November 22, 2016, the Company dismissed BDO LLP (“BDO”) as the Company’s independent registered public accounting firm, effective immediately. On November 22, 2016, the Company appointed Marcum LLP (“Marcum”) as the Company’s new independent registered public accounting firm effective as of November 22, 2016.

 

The Audit Committee of the board of directors of the Company approved the dismissal of BDO and the appointment of Marcum.

 

The reports of BDO on the Company’s financial statements for each of fiscal years ended June 30, 2016 and 2015 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principle.

 

During the fiscal years ended June 30, 2016 and 2015, and the subsequent interim period through November 22, 2016, there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and BDO on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures which disagreements, if not resolved to the satisfaction of BDO would have caused BDO to make reference thereto in their reports on the financial statements for such years.

 

The Company provided BDO with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that BDO furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements contained herein. A copy of BDO’s letter, dated November 28, 2016, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

 

During the fiscal year ended June 30, 2016 and the period from July 1, 2016 through November 28, 2016, neither the Company, nor anyone acting on its behalf, consulted with Marcum regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that may be rendered on the Company’s financial statements, and Marcum did not provide either a written report or oral advice to the Company that was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

 

Item 9.01Financial Statements and Exhibits

 

(d)Exhibits.

 

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

 

Exhibit No. Description
   
16.1 

Letter from BDO LLP dated November 28, 2016

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 28, 2016

 

  RASNA THERAPEUTICS, INC.  
       
       
  By:  /s/ James Tripp  
    Name:  James Tripp  
    Title:   Acting Chief Executive Officer